DDOG vs LLY: Which Is the Better Buy?
Side-by-side comparison of Datadog, Inc. and Eli Lilly and Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-26.
Datadog, Inc. · Technology
$256.92
+28.7% upside to fair value
Med Conviction
Grade C
High Quality
VS
Eli Lilly and Company · Healthcare
$1,183.72
+2.1% upside to fair value
Med Conviction
Grade B
High Quality
QuantHub Verdict
DDOG has more upside to fair value
(+28.7%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DDOG |
LLY |
| Current Price |
$256.92 |
$1,183.72 |
| Fair Value Estimate |
$330.72 |
$1,208.00 |
| Upside to Fair Value |
+28.7%
|
+2.1%
|
| Market Cap |
$91.5B |
$1,114.8B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
350.6x
|
26.8x
|
| Price / Sales |
23.1x
|
14.0x
|
| Price / FCF |
78.9x
|
52.7x
|
| Revenue Growth YoY |
+35.6%
|
+47.7%
|
| Gross Margin |
79.5%
|
83.4%
|
| Operating Margin |
0.4%
|
49.7%
|
| Return on Equity |
4.6%
|
92.6%
|
| Dividend Yield |
0% |
0.57% |
| FCF Yield |
1.27%
|
1.9%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
Datadog is a cloud observability platform that unifies infrastructure monitoring, application performance management, log management, security, and incident response into a single SaaS offering used by developers and IT operations teams across North America and internationally. The business quality is high on the top line: revenue grew 35.6% year over year in the most recent quarter, TTM gross ma…
Eli Lilly is a global pharmaceutical company whose incretin franchise, led by Mounjaro and Zepbound, has become the dominant growth engine in diabetes and obesity care. The business quality is high: TTM gross margin is 83.4%, TTM operating margin is 49.7%, TTM net margin is 33.5%, and ROE is 92.6%, while revenue grew 47.7% and earnings grew 25.3% in the most recent quarter on a year-over-year bas…
Accumulation Zones
| Metric |
DDOG |
LLY |
| Zone Low |
$248.04 |
$906.00 |
| Zone High |
$281.11 |
$1,026.80 |
| In Buy Zone? |
Yes
|
No
|